Основная статистика
| LEI | 5493001TD2TH6VDTJU11 |
| CIK | 1403132 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Wuxi Pharmatech (Cayman) Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| February 10, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) WuXi PharmaTech (Cayman) Inc. (Name of Issuer) ADR (Title of Class of Securities) 929352102 (CUSIP Number) 12/31/15 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| January 11, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* WuXi PharmaTech (Cayman) Inc. (Name of Issuer) Ordinary Shares (Title of Class of Securities) (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| December 21, 2015 |
Wuxi Pharmatech (Cayman) FORM 15-12B Form 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33623 WuXi PharmaTech (Cayman) Inc. (Exact name of registrant |
|
| December 11, 2015 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on December 22, 2015, pursuant to the provisions of Rule 12d2-2 (a). |
|
| December 10, 2015 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* WuXi PharmaTech (Cayman) Inc. (Name of Issuer) Ordinary Shares (Title of Class of Securities) (CUSIP Number) November 30, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| December 10, 2015 |
Wuxi Pharmatech (Cayman) FORM 6-K (Current Report of Foreign Issuer) Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| December 10, 2015 |
Wuxi Pharmatech (Cayman) POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 S-8 POS 1 d95022ds8pos.htm POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 As filed with the Securities and Exchange Commission on December 10, 2015 Registration No. 333-146730 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 WuXi PharmaTech (Cayman) Inc. (Exact name of registrant a |
|
| December 10, 2015 |
SC 13E3/A 1 d86213dsc13e3a.htm AMENDMENT NO.5 TO SCHEDULE 13E-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 5 TO SCHEDULE 13E-3 RULE 13e-3 TRANSACTION STATEMENT (Pursuant to Section 13(e) of the Securities Exchange Act of 1934) WuXi PharmaTech (Cayman) Inc. (Name of the Issuer) WuXi PharmaTech (Cayman) Inc. New WuXi Life Science Holdings Limited New WuXi L |
|
| December 10, 2015 |
Wuxi Pharmatech (Cayman) POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 S-8 POS 1 d104771ds8pos.htm POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 As filed with the Securities and Exchange Commission on December 10, 2015 Registration No. 333-182917 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 WuXi PharmaTech (Cayman) Inc. (Exact name of registrant |
|
| November 25, 2015 |
Wuxi Pharmatech (Cayman) FORM 6-K (Current Report of Foreign Issuer) Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| November 20, 2015 |
EX-99.(B)(25) Exhibit (b)-(25) EXECUTION VERSION U.S.$300,000,000 FACILITY AGREEMENT dated November 20, 2015 for GROUP & CLOUD LIMITED arranged by PING AN BANK CO., LTD. ( ) and SHANGHAI PUDONG DEVELOPMENT BANK CO., LTD. ( ) as Mandated Lead Arrangers with SHANGHAI PUDONG DEVELOPMENT BANK CO., LTD. ( ) as Facility Agent and PING AN BANK CO., LTD. ( ) as Security Agent CONTENTS CLAUSE PAGE SECTION |
|
| November 20, 2015 |
SC 13E3/A 1 d86213dsc13e3a.htm AMENDMENT NO.4 TO SCHEDULE 13E-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO SCHEDULE 13E-3 RULE 13e-3 TRANSACTION STATEMENT (Pursuant to Section 13(e) of the Securities Exchange Act of 1934) WuXi PharmaTech (Cayman) Inc. (Name of the Issuer) WuXi PharmaTech (Cayman) Inc. New WuXi Life Science Holdings Limited New WuXi L |
|
| November 20, 2015 |
SECOND AMENDMENT TO THE AGREEMENT AND PLAN OF MERGER EX-99.(D)(2) Exhibit (d)-(2) SECOND AMENDMENT TO THE AGREEMENT AND PLAN OF MERGER This SECOND AMENDMENT TO THE AGREEMENT AND PLAN OF MERGER, dated as of November 20, 2015 (this “Amendment”), is made by and among New WuXi Life Science Limited, an exempted company with limited liability incorporated under the Law of the Cayman Islands (“Parent”), WuXi Merger Limited, an exempted company with limited |
|
| November 20, 2015 |
EX-99.(B)(24) Exhibit (b)-(24) EXECUTION VERSION U.S.$800,000,000 FACILITY AGREEMENT dated November 20, 2015 for WUXI MERGER LIMITED arranged by PING AN BANK CO., LTD. ( ) and SHANGHAI PUDONG DEVELOPMENT BANK CO., LTD. ( ) as Mandated Lead Arrangers with SHANGHAI PUDONG DEVELOPMENT BANK CO., LTD. ( ) as Facility Agent and PING AN BANK CO., LTD. ( ) as Security Agent CONTENTS CLAUSE PAGE SECTION 1 |
|
| November 12, 2015 |
Wuxi Pharmatech (Cayman) FORM 6-K (Current Report of Foreign Issuer) Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| November 3, 2015 |
Wuxi Pharmatech (Cayman) FORM 6-K (Current Report of Foreign Issuer) Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| October 20, 2015 |
AMENDMENT NO.3 TO SCHEDULE 13E-3 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO SCHEDULE 13E-3 RULE 13e-3 TRANSACTION STATEMENT (Pursuant to Section 13(e) of the Securities Exchange Act of 1934) WuXi PharmaTech (Cayman) Inc. (Name of the Issuer) WuXi PharmaTech (Cayman) Inc. New WuXi Life Science Holdings Limited New WuXi Life Science L |
|
| October 20, 2015 |
EX-99.(A)(1) Table of Contents PROXY STATEMENT OF THE COMPANY Exhibit (a)-(1) October 20, 2015 Shareholders of WuXi PharmaTech (Cayman) Inc. Re: Notice of Extraordinary General Meeting of Shareholders Dear Shareholder: You are cordially invited to attend an extraordinary general meeting of shareholders of WuXi PharmaTech (Cayman) Inc., an exempted company with limited liability incorporated under |
|
| October 20, 2015 |
Wuxi Pharmatech (Cayman) FORM 6-K (Current Report of Foreign Issuer) Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| October 20, 2015 |
SECOND AMENDED AND RESTATED CONSORTIUM AGREEMENT EX-99.(B)(15) Exhibit (b)-(15) EXECUTION VERSION SECOND AMENDED AND RESTATED CONSORTIUM AGREEMENT THIS SECOND AMENDED AND RESTATED CONSORTIUM AGREEMENT, dated as of October 20, 2015 (this “Agreement”), is made by and among Dr. Ge Li (the “Chairman”), ABG II-WX Limited, a company formed under the laws of the British Virgin Islands (“ABG”), Boyu Capital Fund II, L.P., an exempted limited partnership |
|
| October 20, 2015 |
AMENDED AND RESTATED INTERIM INVESTORS AGREEMENT EX-99.(B)(17) Exhibit (b)-(17) EXECUTION VERSION CONFIDENTIAL AMENDED AND RESTATED INTERIM INVESTORS AGREEMENT This Amended and Restated Interim Investors Agreement (this “Agreement”) is made as of October 20, 2015 by and among Dr. Ge Li (the “Chairman”) (solely for the purposes of Section 2.1 and Section 3), G&C Partnership L.P., an exempted limited partnership formed under the laws of the Cayman |
|
| October 9, 2015 |
Amendment No.2 To Schedule 13E-3 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO SCHEDULE 13E-3 RULE 13e-3 TRANSACTION STATEMENT (Pursuant to Section 13(e) of the Securities Exchange Act of 1934) WuXi PharmaTech (Cayman) Inc. (Name of the Issuer) WuXi PharmaTech (Cayman) Inc. New WuXi Life Science Holdings Limited New WuXi Life Science L |
|
| October 9, 2015 |
SEC Letter 787 Seventh Avenue New York, NY 10019-6099 Tel: 212 728 8000 Fax: 212 728 8111 VIA EDGAR October 9, 2015 Securities and Exchange Commission 100 F Street, N. |
|
| October 9, 2015 |
EX-99.(a)(1) PRELIMINARY PROXY STATEMENT OF THE COMPANY Exhibit (a)-(1) [ ], 2015 Shareholders of WuXi PharmaTech (Cayman) Inc. Re: Notice of Extraordinary General Meeting of Shareholders Dear Shareholder: You are cordially invited to attend an extraordinary general meeting of shareholders of WuXi PharmaTech (Cayman) Inc., an exempted company with limited liability incorporated under the laws of t |
|
| September 23, 2015 |
EX-99.(a)(1) PRELIMINARY PROXY STATEMENT OF THE COMPANY Exhibit (a)-(1) [ ], 2015 Shareholders of WuXi PharmaTech (Cayman) Inc. Re: Notice of Extraordinary General Meeting of Shareholders Dear Shareholder: You are cordially invited to attend an extraordinary general meeting of shareholders of WuXi PharmaTech (Cayman) Inc., an exempted company with limited liability incorporated under the laws of t |
|
| September 23, 2015 |
787 Seventh Avenue New York, NY 10019-6099 Tel: 212 728 8000 Fax: 212 728 8111 VIA EDGAR September 23, 2015 Securities and Exchange Commission 100 F Street, N. |
|
| September 23, 2015 |
Amendment No.1 To Schedule 13E-3 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO SCHEDULE 13E-3 RULE 13e-3 TRANSACTION STATEMENT (Pursuant to Section 13(e) of the Securities Exchange Act of 1934) WuXi PharmaTech (Cayman) Inc. (Name of the Issuer) WuXi PharmaTech (Cayman) Inc. New WuXi Life Science Holdings Limited New WuXi Life Science L |
|
| September 1, 2015 |
EX-99.(b)(17) Exhibit (b)-(17) EXECUTION VERSION CONFIDENTIAL LIMITED GUARANTEE LIMITED GUARANTEE, dated as of August 14, 2015 (this “Limited Guarantee”), by Hillhouse Capital Fund II, L.P. (the “Guarantor”) in favor of WuXi PharmaTech (Cayman) Inc., an exempted company with limited liability incorporated under the Laws of the Cayman Islands (the “Guaranteed Party”). 1. GUARANTEE. (a) To induce th |
|
| September 1, 2015 |
AMENDED AND RESTATED CONSORTIUM AGREEMENT EX-99.(b)(12) Exhibit (b)-(12) EXECUTION VERSION AMENDED AND RESTATED CONSORTIUM AGREEMENT THIS AMENDED AND RESTATED CONSORTIUM AGREEMENT, dated as of July 2, 2015 (this “Agreement”), is made by and among Dr. Ge Li (the “Chairman”), ABG Capital Partners II GP, L.P., an exempted limited partnership formed under the laws of the Cayman Islands (“ABG”), Boyu Capital Fund II, L.P., an exempted limited |
|
| September 1, 2015 |
EX-99.(a)(1) PRELIMINARY PROXY STATEMENT OF THE COMPANY Exhibit (a)-(1) [ ], 2015 Shareholders of WuXi PharmaTech (Cayman) Inc. Re: Notice of Extraordinary General Meeting of Shareholders Dear Shareholder: You are cordially invited to attend an extraordinary general meeting of shareholders of WuXi PharmaTech (Cayman) Inc., an exempted company with limited liability incorporated under the laws of t |
|
| September 1, 2015 |
EX-99.(b)(18) Exhibit (b)-(18) EXECUTION VERSION CONFIDENTIAL LIMITED GUARANTEE LIMITED GUARANTEE, dated as of August 14, 2015 (this “Limited Guarantee”), by Ping An Life Insurance Company of China, Ltd. (Registration No.100000000037463) (the “Guarantor”) in favor of WuXi PharmaTech (Cayman) Inc., an exempted company with limited liability incorporated under the Laws of the Cayman Islands (the “Gu |
|
| September 1, 2015 |
EX-99.(b)(19) Exhibit (b)-(19) EXECUTION VERSION CONFIDENTIAL LIMITED GUARANTEE LIMITED GUARANTEE, dated as of August 14, 2015 (this “Limited Guarantee”), by Temasek Life Sciences Private Limited (the “Guarantor”) in favor of WuXi PharmaTech (Cayman) Inc., an exempted company with limited liability incorporated under the Laws of the Cayman Islands (the “Guaranteed Party”). 1. GUARANTEE. (a) To ind |
|
| September 1, 2015 |
EQUITY COMMITMENT LETTER August 14, 2015 EX-99.(b)(4) Exhibit (b)-(4) EXECUTION VERSION CONFIDENTIAL EQUITY COMMITMENT LETTER August 14, 2015 New WuXi Life Science Holdings Limited New WuXi Life Science Limited Address: 288 Fute Zhong Road The China (Shanghai) Pilot Free Trade Zone Shanghai 200131 People’s Republic of China Attention: Ge Li Facsimile: +86-21-50463718 Ladies and Gentlemen: This letter agreement sets forth the commitment o |
|
| September 1, 2015 |
EQUITY COMMITMENT LETTER August 14, 2015 EX-99.(b)(6) Exhibit (b)-(6) EXECUTION VERSION CONFIDENTIAL EQUITY COMMITMENT LETTER August 14, 2015 New WuXi Life Science Holdings Limited New WuXi Life Science Limited Address: 288 Fute Zhong Road The China (Shanghai) Pilot Free Trade Zone Shanghai 200131 People’s Republic of China Attention: Ge Li Facsimile: +86-21-50463718 Ladies and Gentlemen: This letter agreement sets forth the commitment o |
|
| September 1, 2015 |
WX / Wuxi Pharmatech (Cayman) Inc. / WuXi PharmaTech (Cayman) Inc. - SCHEDULE 13E-3 SC 13E3 1 d86213dsc13e3.htm SCHEDULE 13E-3 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 RULE 13e-3 TRANSACTION STATEMENT (Pursuant to Section 13(e) of the Securities Exchange Act of 1934) WuXi PharmaTech (Cayman) Inc. (Name of the Issuer) WuXi PharmaTech (Cayman) Inc. New WuXi Life Science Holdings Limited New WuXi Life Science Limited Wu |
|
| September 1, 2015 |
EX-99.(b)(16) Exhibit (b)-(16) EXECUTION VERSION CONFIDENTIAL LIMITED GUARANTEE LIMITED GUARANTEE, dated as of August 14, 2015 (this “Limited Guarantee”), by Boyu Capital Fund II, L.P. (the “Guarantor”) in favor of WuXi PharmaTech (Cayman) Inc., an exempted company with limited liability incorporated under the Laws of the Cayman Islands (the “Guaranteed Party”). 1. GUARANTEE. (a) To induce the Gua |
|
| September 1, 2015 |
EX-99.(b)(11) Exhibit (b)-(11) EXECUTION VERSION CONSORTIUM AGREEMENT THIS CONSORTIUM AGREEMENT, dated as of May 11, 2015 (this “Agreement”), is made by and among Dr. Ge Li (the “Chairman”), ABG Capital Partners II GP, L.P., an exempted limited partnership formed under the laws of the Cayman Islands (“ABG”) and Boyu Capital Fund II, L.P., an exempted limited partnership formed under the laws of th |
|
| September 1, 2015 |
[Signature Page to the Commitment Letter (Management Facility)] EX-99.(b)(2) Exhibit (b)-(2) EXECUTION VERSION STRICTLY PRIVATE AND CONFIDENTIAL To: Group & Cloud Limited (the “Borrower”) 288 Fute Zhong Road Waigaoqiao Free Trade Zone Shanghai 200131, China Attention: Mr. Li Ge 14 August 2015 Dear Sirs: Project Super – Commitment Letter We, Ping An Bank Co., Ltd. and Shanghai Pudong Development Bank Co., Ltd. (the “Mandated Lead Arrangers”) and Ping An Bank Co |
|
| September 1, 2015 |
EQUITY COMMITMENT LETTER August 14, 2015 EX-99.(b)(8) Exhibit (b)-(8) EXECUTION VERSION CONFIDENTIAL EQUITY COMMITMENT LETTER August 14, 2015 New WuXi Life Science Holdings Limited New WuXi Life Science Limited Address: 288 Fute Zhong Road The China (Shanghai) Pilot Free Trade Zone Shanghai 200131 People’s Republic of China Attention: Ge Li Facsimile: +86-21-50463718 Ladies and Gentlemen: This letter agreement sets forth the commitment o |
|
| September 1, 2015 |
EQUITY COMMITMENT LETTER August 14, 2015 EX-99.(b)(9) Exhibit (b)-(9) EXECUTION VERSION CONFIDENTIAL EQUITY COMMITMENT LETTER August 14, 2015 Group & Cloud Limited Address: 288 Fute Zhong Road The China (Shanghai) Pilot Free Trade Zone Shanghai 200131 People’s Republic of China Attention: Ge Li Facsimile: +86-21-50463718 Ladies and Gentlemen: This letter agreement sets forth the commitment of Dr. Ge Li (the “Borrower Shareholder”), on th |
|
| September 1, 2015 |
EX-99.(c)(2) Exhibit (c)-(2) CREDIT SUISSE Project Super Presentation to the Special Committee of the Board of Directors Confidential August 13, 2015 These materials may not be used or relied upon for any purpose other than as specifically contemplated by a written agreement with Credit Suisse AG or its Affiliates (hereafter “Credit Suisse”). Table of contents 1. Transaction overview 2. Super publ |
|
| September 1, 2015 |
EQUITY COMMITMENT LETTER August 14, 2015 EX-99.(B)(7) 9 d86213dex99b7.htm EX-99.(B)(7) Exhibit (b)-(7) EXECUTION VERSION CONFIDENTIAL EQUITY COMMITMENT LETTER August 14, 2015 New WuXi Life Science Holdings Limited New WuXi Life Science Limited Address: 288 Fute Zhong Road The China (Shanghai) Pilot Free Trade Zone Shanghai 200131 People’s Republic of China Attention: Ge Li Facsimile: +86-21-50463718 Ladies and Gentlemen: This letter agre |
|
| September 1, 2015 |
EX-99.(b)(15) Exhibit (b)-(15) EXECUTION VERSION CONFIDENTIAL LIMITED GUARANTEE LIMITED GUARANTEE, dated as of August 14, 2015 (this “Limited Guarantee”), by ABG II-WX Limited (the “Guarantor”) in favor of WuXi PharmaTech (Cayman) Inc., an exempted company with limited liability incorporated under the Laws of the Cayman Islands (the “Guaranteed Party”). 1. GUARANTEE. (a) To induce the Guaranteed P |
|
| September 1, 2015 |
EX-99.(b)(14) Exhibit (b)-(14) EXECUTION VERSION CONFIDENTIAL INTERIM INVESTORS AGREEMENT This Interim Investors Agreement (this “Agreement”) is made as of August 14, 2015 by and among Dr. Ge Li (the “Chairman”) (solely for the purposes of Section 2.1 and Section 3), G&C Partnership L.P., an exempted limited partnership formed under the laws of the Cayman Islands (the “Management Roll-over Entity” |
|
| September 1, 2015 |
[Signature Page to the Commitment Letter (LBO Facility)] EX-99.(b)(1) Exhibit (b)-(1) EXECUTION VERSION STRICTLY PRIVATE AND CONFIDENTIAL To: WuXi Merger Limited (the “Borrower”) c/o Codan Trust Company (Cayman) Limited Cricket Square, Hutchins Drive PO Box 2681 Grand Cayman, KY1-1111, Cayman Islands Attention: Ge Li 14 August 2015 Dear Sirs: Project Super – Commitment Letter We, Ping An Bank Co., Ltd. and Shanghai Pudong Development Bank Co., Ltd. (the |
|
| September 1, 2015 |
EQUITY COMMITMENT LETTER August 14, 2015 EX-99.(b)(5) Exhibit (b)-(5) EXECUTION VERSION CONFIDENTIAL EQUITY COMMITMENT LETTER August 14, 2015 New WuXi Life Science Holdings Limited New WuXi Life Science Limited Address: 288 Fute Zhong Road The China (Shanghai) Pilot Free Trade Zone Shanghai 200131 People’s Republic of China Attention: Ge Li Facsimile: +86-21-50463718 Ladies and Gentlemen: This letter agreement sets forth the commitment o |
|
| September 1, 2015 |
EX-99.(c)(1) Exhibit (c)-(1) CREDIT SUISSE Project Super Discussion Materials for the Special Committee of the Board of Directors Confidential / Draft July 13, 2015 PRELIMINARY | SUBJECT TO FURTHER REVIEW AND EVALUATION These materials may not be used or relied upon for any purpose other than as specifically contemplated by a written agreement with Credit Suisse AG or its Affiliates (hereafter “Cr |
|
| September 1, 2015 |
EQUITY COMMITMENT LETTER August 14, 2015 EX-99.(b)(3) Exhibit (b)-(3) EXECUTION VERSION CONFIDENTIAL EQUITY COMMITMENT LETTER August 14, 2015 New WuXi Life Science Holdings Limited New WuXi Life Science Limited Address: 288 Fute Zhong Road The China (Shanghai) Pilot Free Trade Zone Shanghai 200131 People’s Republic of China Attention: Ge Li Facsimile: +86-21-50463718 Ladies and Gentlemen: This letter agreement sets forth the commitment o |
|
| September 1, 2015 |
EX-99.(b)(20) Exhibit (b)-(20) EXECUTION VERSION CONFIDENTIAL LIMITED GUARANTEE LIMITED GUARANTEE, dated as of August 14, 2015 (this “Limited Guarantee”), by Dr. Ge Li (the “Guarantor”) in favor of WuXi PharmaTech (Cayman) Inc., an exempted company with limited liability incorporated under the Laws of the Cayman Islands (the “Guaranteed Party”). 1. GUARANTEE. (a) To induce the Guaranteed Party to |
|
| September 1, 2015 |
AMENDMENT TO THE AMENDED AND RESTATED CONSORTIUM AGREEMENT EX-99.(b)(13) Exhibit (b)-(13) EXECUTION VERSION AMENDMENT TO THE AMENDED AND RESTATED CONSORTIUM AGREEMENT This AMENDMENT TO THE AMENDED AND RESTATED CONSORTIUM AGREEMENT, dated as of August 14, 2015 (this “Amendment”), is made by and among Dr. Ge Li (the “Chairman”), ABG Capital Partners II GP, L.P., an exempted limited partnership formed under the laws of the Cayman Islands (“ABG”), Boyu Capita |
|
| August 17, 2015 |
Wuxi Pharmatech (Cayman) FORM 6-K (Current Report of Foreign Issuer) Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| August 14, 2015 |
Wuxi Pharmatech (Cayman) FORM 6-K (Current Report of Foreign Issuer) Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| August 14, 2015 |
WUXI PHARMATECH ENTERS INTO DEFINITIVE MERGER AGREEMENT EX-99.1 Exhibit 99.1 WUXI PHARMATECH ENTERS INTO DEFINITIVE MERGER AGREEMENT SHANGHAI, August 14, 2015 ? WuXi PharmaTech (Cayman) Inc. (?WuXi? or the ?Company?) (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced that it has entered i |
|
| August 14, 2015 |
EX-99.2 Exhibit 99.2 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among NEW WUXI LIFE SCIENCE LIMITED, WUXI MERGER LIMITED and WUXI PHARMATECH (CAYMAN) INC. Dated as of August 14, 2015 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 Section 1.01 The Merger 2 Section 1.02 Closing; Closing Date 2 Section 1.03 Effective Time 2 Section 1.04 Effects of the Merger 2 Section 1.05 Memorandum and Articles |
|
| July 10, 2015 |
Wuxi Pharmatech (Cayman) FORM 6-K (Current Report of Foreign Issuer) Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| May 22, 2015 |
Wuxi Pharmatech (Cayman) FORM 6-K (Current Report of Foreign Issuer) Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| May 14, 2015 |
Wuxi Pharmatech (Cayman) FORM 6-K (Current Report of Foreign Issuer) Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| May 13, 2015 |
Wuxi Pharmatech (Cayman) FORM 6-K (Current Report of Foreign Issuer) Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| April 30, 2015 |
Wuxi Pharmatech (Cayman) FORM 6-K (Current Report of Foreign Issuer) Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| April 15, 2015 |
Exhibit 13.1 Certification by the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Ge Li, Chief Executive Officer of WuXi PharmaTech (Cayman) Inc. (the ?Company?), hereby certifies, to the best of his knowledge, that the Company?s annual report |
|
| April 15, 2015 |
Exhibit 13.2 Certification by the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Edward Hu, Acting Chief Financial Officer of WuXi PharmaTech (Cayman) Inc. (the ?Company?), hereby certifies, to the best of his knowledge, that the Company?s an |
|
| April 15, 2015 |
EXHIBIT 4.22 Execution Version Dated 16 February 2015 WUXI PHARMATECH (CAYMAN) INC. AS BORROWER WUXI APPTEC HOLDING COMPANY, INC. WUXI APPTEC, INC. WUXI APPTEC (BVI) INC. WUXI APPTEC (HONG KONG) LIMITED AS ORIGINAL GUARANTORS CITIGROUP GLOBAL MARKETS ASIA LIMITED AS COORDINATING ARRANGER AND CITICORP INTERNATIONAL LIMITED AS AGENT FACILITY AGREEMENT FOR US$165,000,000 SENIOR TERM AND REVOLVING LOA |
|
| April 15, 2015 |
Exhibit 12.2 Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Edward Hu, certify that: 1. I have reviewed this annual report of WuXi PharmaTech (Cayman) Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the c |
|
| April 15, 2015 |
Exhibit 12.1 Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Ge Li, certify that: 1. I have reviewed this annual report of WuXi PharmaTech (Cayman) Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circu |
|
| April 15, 2015 |
Wuxi Pharmatech (Cayman) FORM 6-K (Current Report of Foreign Issuer) Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| April 15, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F Form 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 10, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* WuXi PharmaTech (Cayman) Inc. (Name of Issuer) Ordinary Shares (Title of Class of Securities) (CUSIP Number) March 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| April 3, 2015 |
Wuxi Pharmatech (Cayman) FORM 6-K (Current Report of Foreign Issuer) Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| March 9, 2015 |
Wuxi Pharmatech (Cayman) FORM 6-K (Current Report of Foreign Issuer) Form 6-K Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| February 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) WuXi PharmaTech (Cayman) Inc. (Name of Issuer) ADR (Title of Class of Securities) 929352102 (CUSIP Number) 12/31/14 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 12, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* WuXi PharmaTech (Cayman) Inc. (Name of Issuer) Ordinary Shares (Title of Class of Securities) (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| January 12, 2015 |
WX / Wuxi Pharmatech (Cayman) Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K 6-K 1 d850738d6k.htm FORM 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2015 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republi |
|
| January 12, 2015 |
WX / Wuxi Pharmatech (Cayman) Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| December 4, 2014 |
WX / Wuxi Pharmatech (Cayman) Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K 6-K 1 d833374d6k.htm FORM 6-K Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2014 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republ |
|
| November 13, 2014 |
WX / Wuxi Pharmatech (Cayman) Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| November 12, 2014 |
WX / Wuxi Pharmatech (Cayman) Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| October 2, 2014 |
WX / Wuxi Pharmatech (Cayman) Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K 6-K 1 d798509d6k.htm FORM 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2014 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republi |
|
| October 2, 2014 |
WX / Wuxi Pharmatech (Cayman) Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K 6-K 1 d798519d6k.htm FORM 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2014 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republi |
|
| October 1, 2014 |
WX / Wuxi Pharmatech (Cayman) Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| August 14, 2014 |
WX / Wuxi Pharmatech (Cayman) Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2014 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of China (Address of principal executi |
|
| August 11, 2014 |
WX / Wuxi Pharmatech (Cayman) Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| July 9, 2014 |
WX / Wuxi Pharmatech (Cayman) Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| May 15, 2014 |
Current Report of Foreign Issuer - FORM 6-K 6-K 1 d726149d6k.htm FORM 6-K Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2014 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of |
|
| April 15, 2014 |
EX-13.2 Exhibit 13.2 Certification by the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Edward Hu, Acting Chief Financial Officer of WuXi PharmaTech (Cayman) Inc. (the Company), hereby certifies, to the best of his knowledge, that the Comp |
|
| April 15, 2014 |
EX-12.1 Exhibit 12.1 Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Ge Li, certify that: 1. I have reviewed this annual report of WuXi PharmaTech (Cayman) Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of t |
|
| April 15, 2014 |
Form 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 15, 2014 |
EX-13.1 Exhibit 13.1 Certification by the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Ge Li, Chief Executive Officer of WuXi PharmaTech (Cayman) Inc. (the “Company”), hereby certifies, to the best of his knowledge, that the Company’s annua |
|
| April 15, 2014 |
EX-12.2 Exhibit 12.2 Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Edward Hu, certify that: 1. I have reviewed this annual report of WuXi PharmaTech (Cayman) Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light |
|
| March 6, 2014 |
Current Report of Foreign Issuer - FORM 6-K Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| February 13, 2014 |
EX-99.2 3 d675420dex992.htm EX-99.2 Exhibit 99.2 Item 7 Information The securities being reported on by the reporting persons herein as parent holding companies are owned, or may be deemed to be beneficially owned as follows: Company Type of Company . First State Investment Management (UK) Limited IA (UK registered) First State Investments (Hong Kong) Limited IA (HK registered) |
|
| February 13, 2014 |
SC 13G 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* WuXi PharmaTech (Cayman) Inc (Name of Issuer) ADR (Title of Class of Securities) 929352102 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 13, 2014 |
WX / Wuxi Pharmatech (Cayman) Inc. / COMMONWEALTH BANK OF AUSTRALIA - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 WuXi PharmaTech (Cayman) Inc. (Name of Issuer) Ordinary Shares, par value U.S.$0.02 per share (represented by American Depository Shares, each representing eight Ordinary Shares). (Title of Class |
|
| February 13, 2014 |
Joint Filing Agreement February 13, 2014 EX-99.1 Exhibit 99.1 Joint Filing Agreement February 13, 2014 In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, Commonwealth Bank of Australia, Colonial Holding Company Limited, Commonwealth Insurance Holdings Limited, Colonial First State Group Limited, and First State Investment Management (UK) Limited each hereby agree to the joint filing of this stateme |
|
| January 13, 2014 |
Current Report of Foreign Issuer - FORM 6-K Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2014 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of China (Address of principal execut |
|
| November 13, 2013 |
Current Report of Foreign Issuer - FORM 6-K 6-K 1 d627894d6k.htm FORM 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2013 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republ |
|
| November 8, 2013 |
Current Report of Foreign Issuer - FORM 6-K Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| September 26, 2013 |
Current Report of Foreign Issuer - FORM 6-K Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| August 13, 2013 |
Current Report of Foreign Issuer - FORM 6-K Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| May 23, 2013 |
Current Report of Foreign Issuer - FORM 6-K Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| May 23, 2013 |
Current Report of Foreign Issuer - FORM 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2013 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of China (Address of principal e |
|
| April 17, 2013 |
EX-13.1 Exhibit 13.1 Certification by the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Ge Li, Chief Executive Officer of WuXi PharmaTech (Cayman) Inc. (the “Company”), hereby certifies, to the best of his knowledge, that the Company’s annua |
|
| April 17, 2013 |
EX-12.1 Exhibit 12.1 Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Ge Li, certify that: 1. I have reviewed this annual report of WuXi PharmaTech (Cayman) Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of t |
|
| April 17, 2013 |
EX-13.2 Exhibit 13.2 Certification by the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Edward Hu, Acting Chief Financial Officer of WuXi PharmaTech (Cayman) Inc. (the “Company”), hereby certifies, to the best of his knowledge, that the Comp |
|
| April 17, 2013 |
EX-12.2 Exhibit 12.2 Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Edward Hu, certify that: 1. I have reviewed this annual report of WuXi PharmaTech (Cayman) Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light |
|
| April 17, 2013 |
Form 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 14, 2013 |
EX-99.2 CUSIP NO. 929352102 13G Page 14 of 14 Exhibit 99.2 Item 7 Information The securities being reported on by the reporting persons herein as parent holding companies are owned, or may be deemed to be beneficially owned as follows: Company Type of Company First State Investment Management (UK) Limited IA (UK registered) First State Investments (Hong Kong) Limited IA (HK registered) |
|
| February 14, 2013 |
Joint Filing Agreement February 14, 2013 EX-99.1 CUSIP NO. 929352102 13G Page 13 of 14 Exhibit 99.1 Joint Filing Agreement February 14, 2013 In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, Commonwealth Bank of Australia, Colonial Holding Company Limited, Commonwealth Insurance Holdings Limited, Colonial First State Group Limited, and First State Investment Management (UK) Limited each hereby agr |
|
| February 14, 2013 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 WuXi PharmaTech (Cayman) Inc. (Name of Issuer) Ordinary Shares, par value U.S.$0.02 per share (represented by American Depository Shares, each representing eight Ordinary Shares). (Title of |
|
| January 23, 2013 |
WuXi PharmaTech (Cayman) Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Wuxi PharmaTech, Inc. (Name of Issuer) Common Stock, Par Value $0.02 per share (Title of Class of Securities) 929352102 (CUSIP Number) 12/31/2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| November 14, 2012 |
Current Report of Foreign Issuer - FORM 6-K Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| November 7, 2012 |
Current Report of Foreign Issuer - FORM 6-K Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| October 9, 2012 |
Current Report of Foreign Issuer - FORM 6-K Form 6-K Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| August 14, 2012 |
Current Report of Foreign Issuer - FORM 6-K Form 6-K Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| July 30, 2012 |
WUXI PHARMATECH (CAYMAN) INC. 2007 EMPLOYEE SHARE INCENTIVE PLAN WuXi PharmaTech (Cayman) Inc. 2007 Employee Share Incentive Plan Exhibit 4 WUXI PHARMATECH (CAYMAN) INC. 2007 EMPLOYEE SHARE INCENTIVE PLAN 1. PURPOSE OF PLAN The purpose of this WuXi PharmaTech (Cayman) Inc. 2007 Employee Share Incentive Plan (this “Plan”) of WuXi PharmaTech (Cayman) Inc., an exempted company organized under the Companies Law (2004 Revision) of the Cayman Islands, and its success |
|
| July 30, 2012 |
FORM S-8 As filed with the Securities and Exchange Commission on July 30, 2012 Registration No. |
|
| May 15, 2012 |
Current Report of Foreign Issuer - FORM 6-K Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| April 20, 2012 |
CEO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12. |
|
| April 20, 2012 |
CFO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12. |
|
| April 20, 2012 |
Form 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 20, 2012 |
CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13. |
|
| April 20, 2012 |
CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13. |
|
| March 12, 2012 |
Current Report of Foreign Issuer - FORM 6-K Form 6-K Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| February 21, 2012 |
Current Report of Foreign Issuer - FORM 6-K Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2012 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of China (Address of principal execu |
|
| February 14, 2012 |
WX / Wuxi Pharmatech (Cayman) Inc. / KYLIN FUND L P - FEBRUARY 14, 2012 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) Information to be included in statements filed pursuant to Rules 13d-1(b), (c) and (d) and amendments thereto filed pursuant to 13d-2(b) (AMENDMENT NO.2)* WuXi PharmaTech (Cayman) Inc. (Name of Issuer) American Depositary Receipts, Each Representing Eight Ordinary Shares (Title of Class of Securit |
|
| February 10, 2012 |
WX / Wuxi Pharmatech (Cayman) Inc. / GENERAL ATLANTIC LLC - AMENDMENT NO. 3 Passive Investment SC 13G/A 1 eh120020913ga3-wuxi.htm AMENDMENT NO. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* WuXi PharmaTech (Cayman) Inc. (Name of Issuer) Ordinary Shares, par value $0.02 per share (Title of Class of Securities) 929352102 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of |
|
| January 27, 2012 |
Wuxi PharmaTech Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Wuxi PharmaTech, Inc. (Name of Issuer) Common Stock, Par Value $.02 per share (Title of Class of Securities) 929352102 (CUSIP Number) 12/31/2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| January 12, 2012 |
Current Report of Foreign Issuer - FORM 6-K Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2012 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of China (Address of principal execut |
|
| January 10, 2012 |
Current Report of Foreign Issuer - FORM 6-K Form 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| December 27, 2011 |
Correspondence December 27, 2011 VIA EMAIL AND ELECTRONIC TRANSMISSION Mr. Jim B. Rosenberg Senior Assistant Chief Accountant Division of Corporation Finance United States Securities and Exchange Commission Washington, DC 20549 Re: WuXi PharmaTech (Cayman) Inc. — Form 20-F filed on April 27, 2011 (File No. 001-33623) Dear Mr. Rosenberg, On behalf of WuXi PharmaTech (Cayman) Inc. (the “Company”), t |
|
| December 12, 2011 |
WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of China December 12, 2011 VIA EMAIL AND ELECTRONIC TRANSMISSION Securities and Exchange Commission Division of Corporate Finance Washington, D.C. 20549 Attention: Jim B. Rosenberg, Senior Assistant Chief Accountant Re: WuXi PharmaTech (Cayman) Inc. — Form 20-F filed on April 27, 2011 (Fi |
|
| August 12, 2011 |
6-K 1 d6k.htm FORM 6-K Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2011 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of Chi |
|
| August 10, 2011 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| June 21, 2011 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| May 12, 2011 |
6-K 1 d6k.htm FORM 6-K Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2011 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of China |
|
| April 27, 2011 |
Certification Exhibit 13.1 Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Ge Li, Chief Executive Officer of WuXi PharmaTech (Cayman) Inc. (the “Company”), hereby certifies, to the best of his knowledge, that the Company’s annual report on Form 20-F for the year ended December 31, 2010 (the “Report”) fully com |
|
| April 27, 2011 |
Certification Exhibit 13.2 Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Edward Hu, Acting Chief Financial Officer of WuXi PharmaTech (Cayman) Inc. (the “Company”), hereby certifies, to the best of his knowledge, that the Company’s annual report on Form 20-F for the year ended December 31, 2010 (the “Report” |
|
| April 27, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F 20-F 1 d20f.htm FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 OR ¨ TRANSITION REPORT PURSUANT |
|
| April 27, 2011 |
Certification Exhibit 12.2 Certification I, Edward Hu, certify that: 1. I have reviewed this annual report of WuXi PharmaTech (Cayman) Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with res |
|
| April 27, 2011 |
Certification Exhibit 12.1 Certification I, Ge Li, certify that: 1. I have reviewed this annual report of WuXi PharmaTech (Cayman) Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect |
|
| March 10, 2011 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| February 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) Information to be included in statements filed pursuant to Rules 13d-1(b), (c) and (d) and amendments thereto filed pursuant to 13d-2(b) (AMENDMENT NO. 1)* WuXi PharmaTech (Cayman) Inc. (Name of Issuer) Ordinary Shares, par value U.S.$0.02 (Title of Class of Securities) 929352102 (CUSIP Number) De |
|
| February 11, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* WuXi PharmaTech (Cayman) Inc. (Name of Issuer) Ordinary Shares, par value $0.02 per share (Title of Class of Securities) 929352102 (CUSIP Number) December 31, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| January 11, 2011 |
6-K 1 d6k.htm FORM 6-K Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2011 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of Ch |
|
| November 16, 2010 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 4) Under the Securities Exchange Act of 1934* WuXi PharmaTech (Cayman) Inc. (Name of Issuer) Ordinary Shares, Par Value $0.02 Per Share (Title of Class of Securities) 929352102 (CUSIP Number) Scott A. Arenare, Esq. Managing Director and General Counsel Warburg Pincus LLC 450 Lexington Avenue New York, NY 10017 |
|
| November 15, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) Information to be included in statements filed pursuant to Rules 13d-1(b), (c) and (d) and amendments thereto filed pursuant to 13d-2(b) (AMENDMENT NO. )* WuXi PharmaTech (Cayman) Inc. (Name of Issuer) Ordinary Shares, par value U.S.$0.02 (Title of Class of Securities) 929352102 (CUSIP Number) Nov |
|
| November 12, 2010 |
6-K 1 d6k.htm FORM 6-K Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2010 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of C |
|
| November 12, 2010 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| October 14, 2010 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| August 12, 2010 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| August 5, 2010 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| August 2, 2010 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 3) Under the Securities Exchange Act of 1934* WuXi PharmaTech (Cayman) Inc. (Name of Issuer) Ordinary Shares, Par Value $0.02 Per Share (Title of Class of Securities) 929352102 (CUSIP Number) Scott A. Arenare, Esq. Managing Director and General Counsel Warburg Pincus LLC 450 Lexington Avenue New York, NY 10017 |
|
| July 30, 2010 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2010 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People?s Republic of China (Address of principal executive office) |
|
| July 15, 2010 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2010 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People?s Republic of China (Address of principal executive office) |
|
| July 14, 2010 |
Form 6-K Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2010 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of China (Address of principal executive |
|
| July 13, 2010 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2010 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of China (Address of principal executive office) |
|
| July 1, 2010 |
6-K 1 d6k.htm FORM 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2010 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of China |
|
| June 29, 2010 |
6-K 1 d6k.htm FORM 6-K Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2010 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of China |
|
| June 24, 2010 |
6-K 1 d6k.htm FORM 6-K Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2010 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of China (Address of princ |
|
| June 24, 2010 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2010 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of China (Address of principal executive office) |
|
| June 14, 2010 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| June 11, 2010 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| June 1, 2010 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2010 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of China (Address of principal executive office) |
|
| June 1, 2010 |
Form 6-K Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| May 12, 2010 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| May 5, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 WuXi PharmaTech (Cayman) Inc. (Name of Issuer) Ordinary Shares, $0.02 Par Value Per Share American Depositary Shares (Title of Class of Securities) 929352102 (CUSIP Number) Matthew Daniel 251 Ballardvale Street Wilmington, Massachusetts, 01887 Tel. No. (781) 222-6000 (Name |
|
| April 27, 2010 |
Exhibit 6 EXECUTION COPY VOTING AGREEMENT AGREEMENT, dated as of April 26, 2010 between Charles River Laboratories International, Inc. |
|
| April 27, 2010 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 2) Under the Securities Exchange Act of 1934* WuXi PharmaTech (Cayman) Inc. (Name of Issuer) Ordinary Shares, Par Value $0.02 Per Share (Title of Class of Securities) 929352102 (CUSIP Number) Scott A. Arenare, Esq. Managing Director and General Counsel Warburg Pincus LLC 450 Lexington Avenue New York, NY 10017 |
|
| April 27, 2010 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| April 26, 2010 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| April 23, 2010 |
CFO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Exhibit 12.2 Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Edward Hu, certify that: 1. I have reviewed this annual report of WuXi PharmaTech (Cayman) Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to s |
|
| April 23, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| April 23, 2010 |
CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Exhibit 13.1 Certification by the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Ge Li, Chief Executive Officer of WuXi PharmaTech (Cayman) Inc. (the “Company”), her |
|
| April 23, 2010 |
Exhibit 12.1 Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Ge Li, certify that: 1. I have reviewed this annual report of WuXi PharmaTech (Cayman) Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circu |
|
| April 23, 2010 |
CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Exhibit 13.2 Certification by the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Edward Hu, Acting Chief Financial Officer of WuXi PharmaTech (Cayman) Inc. (the “Com |
|
| March 10, 2010 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| February 12, 2010 |
SC 13G/A 1 sc13ga1wuxi.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* WuXi PharmaTech (Cayman) Inc. (Name of Issuer) Ordinary Shares, par value $0.02 per share (Title of Class of Securities) 929352102 (CUSIP Number) December 31, 2009 (Date of Event which Requires Filing of this St |
|
| February 5, 2010 |
SC 13G/A 1 dsc13ga.htm SCHEDULE 13G AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 2) Under the Securities Exchange Act of 1934 WuXi PharmaTech (Cayman) Inc. (Name of Issuer) Ordinary Shares* American Depositary Shares (Title of class of securities) 929352102** (CUSIP number) December 31, 2009 (Date of event which requires filing |
|
| November 20, 2009 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| September 21, 2009 |
CORRESP 1 filename1.htm WUXI PHARMATECH (CAYMAN) INC. 288 FUTE ZHONG ROAD WAIGAOQIAO FREE TRADE ZONE SHANGHAI 200131 PEOPLE’S REPUBLIC OF CHINA September 21, 2009 VIA EDGAR AND FACSIMILE Mail Stop 4720 United States Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Attention: Jeffrey P. Reidler, Assistant Director Scot Foley Re: WuXi PharmaTech (Cayman) Inc. Registration |
|
| September 18, 2009 |
As filed with the Securities and Exchange Commission on September 18, 2009 Table of Contents As filed with the Securities and Exchange Commission on September 18, 2009 Registration No. |
|
| September 4, 2009 |
As filed with the Securities and Exchange Commission on September 4, 2009 F-3 1 df3.htm FORM F-3 Table of Contents As filed with the Securities and Exchange Commission on September 4, 2009 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 WuXi PharmaTech (Cayman) Inc. Not Applicable (Translation of Registrant’s name into English) Cayman Islands 2834 N/A (State or |
|
| August 13, 2009 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| August 10, 2009 |
Form 6-K Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| July 13, 2009 |
Form 6-K Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| June 25, 2009 |
EXHIBIT 4.18 FIRST AMENDMENT TO LEASE This First Amendment to Lease (this ?Amendment?) dated June 10, 2008 is between 1201 Northland Drive LLC, a Minnesota limited liability company (?Landlord?), and WuXi AppTec, Inc., a Delaware corporation (?Tenant?). Recitals: A. Landlord and Tenant are the parties to the Lease Agreement dated August 31, 2007 (the ?Original Lease?) that covers approximately 62, |
|
| June 25, 2009 |
SECOND AMENDMENT TO OFFICE AND INDUSTRIAL LEASE AGREEMENT EXHIBIT 4.14 SECOND AMENDMENT TO OFFICE AND INDUSTRIAL LEASE AGREEMENT THIS AMENDMENT is entered into on December 30, 2008, by and between LIBERTY PROPERTY PHILADELPHIA LIMITED PARTNERSHIP V, a Pennsylvania limited partnership (?Landlord?) and WUXI APPTEC INC., a corporation organized under the laws of Delaware (?Tenant?), successor to APPTEC LABORATORY SERVICES, LLC, a limited liability company o |
|
| June 25, 2009 |
EXHIBIT 12.2 Certification by the Acting Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Edward Hu, Acting Chief Financial Officer of WuXi PharmaTech (Cayman) Inc. (the ?Company?), certify that: 1. I have reviewed this annual report on Form 20-F of the Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omi |
|
| June 25, 2009 |
CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13. |
|
| June 25, 2009 |
EXHIBIT 13.2 Certification by the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Edward Hu, Acting Chief Financial Officer of WuXi PharmaTech (Cayman) Inc. (the ?Company?), hereby certifies, to the best of his knowledge, that the Company?s an |
|
| June 25, 2009 |
CEO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 EXHIBIT 12. |
|
| June 25, 2009 |
EXHIBIT 4.16 SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this ?Amendment?) is made as of April 30, 2008 (the ?Amendment Date?) by and between ALPHA EXCHANGE, LLC, a Georgia limited liability company (successor-in-interest to Highwoods Realty Limited Partnership) (?Landlord?) and WUXI APPTEC, INC., a Delaware corporation (f/k/a Apptec Laboratory Services, Inc., a Delaware corporation) |
|
| June 25, 2009 |
EXHIBIT 1.1 THE COMPANIES LAW (2007 REVISION) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES SECOND AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF WUXI PHARMATECH (CAYMAN) INC. Adopted by Special Resolution passed on July 27, 2007 and effective immediately upon completion of the Company?s initial public offering of ordinary shares represented by American Depositary Shares Note: This document a |
|
| June 25, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2008 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| June 25, 2009 |
WUXI PHARMATECH (BVI) INC. CONVERTIBLE NOTE Exhibit 4.3 EXECUTION VERSION THIS NOTE AND THE SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. THEY MAY NOT BE TRANSFERRED, SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND APP |
|
| May 15, 2009 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| March 26, 2009 |
6-K 1 d6k.htm FORM 6-K Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2009 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of Chin |
|
| February 20, 2009 |
6-K 1 d6k.htm FORM 6-K Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2009 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of C |
|
| February 13, 2009 |
EXHIBIT A Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the ordinary shares, par value US$0. |
|
| February 13, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) WuXi PharmaTech (Cayman) Inc. (Name of Issuer) Ordinary Shares* American Depositary Shares (Title of Class of Securities) 929352102** (CUSIP Number) December 31, 2008 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| February 11, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1) Under the Securities Exchange Act of 1934 WuXi PharmaTech (Cayman) Inc. (Name of Issuer) Ordinary Shares* American Depositary Shares (Title of Class of Securities) 929352102** (CUSIP Number) December 31, 2008 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| February 11, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1) Under the Securities Exchange Act of 1934 WuXi PharmaTech (Cayman) Inc. (Name of Issuer) Ordinary Shares* American Depositary Shares (Title of Class of Securities) 929352102** (CUSIP Number) December 31, 2008 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| February 6, 2009 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| December 2, 2008 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| November 13, 2008 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| October 14, 2008 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| September 29, 2008 |
6-K 1 d6k.htm FORM 6-K Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2008 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of |
|
| August 18, 2008 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| August 8, 2008 |
6-K 1 d6k.htm FORM 6-K Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2008 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of Chi |
|
| August 5, 2008 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| July 14, 2008 |
EXHIBIT 1 JOINT FILING AGREEMENT THIS JOINT FILING AGREEMENT is entered into as of July 14, 2008, by and among the parties hereto. |
|
| July 14, 2008 |
Exhibit 2 Execution Version SHARE PURCHASE AGREEMENT SHARE PURCHASE AGREEMENT (the ?Agreement?), dated as of June 1, 2008, by and among the parties listed in Schedule 1 (the ?Selling Shareholders? and each individually a ?Selling Shareholder?) and Warburg Pincus Private Equity X, L. |
|
| July 14, 2008 |
AMENDMENT NO. 1 TO THE SHARE PURCHASE AGREEMENT Exhibit 3 AMENDMENT NO. 1 TO THE SHARE PURCHASE AGREEMENT AMENDMENT AGREEMENT (the ?Amendment Agreement?), dated as of July 2, 2008, by and among Warburg Pincus Private Equity X, L.P., a Delaware limited partnership, and Warburg Pincus X Partners, L.P., a Delaware limited partnership (together, the ?Buyers?), UOB Hermes Asia Technology Fund, a Cayman Islands exempted company, UOB JAIC Venture Bio |
|
| July 14, 2008 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934* WuXi PharmaTech (Cayman) Inc. (Name of Issuer) Ordinary Shares, Par Value $0.02 Per Share (Title of Class of Securities) 929352102 (CUSIP Number) Scott A. Arenare, Esq. Managing Director and General Counsel Warburg Pincus LLC 466 Lexington Avenue New York, NY 10017 (212) 878-0600 (Name |
|
| July 7, 2008 |
WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of China July 7, 2008 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. H. Christopher Owings Ms. Peggy Kim Re: WuXi PharmaTech (Cayman) Inc. Registration Statement on Form F-1 (File No. 333-150076) Application for Withdrawal of Re |
|
| June 25, 2008 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| June 16, 2008 |
EX-4.13 2 dex413.htm OFFICE AND INDUSTRIAL LEASE AGREEMENT DATED AS OF DECEMBER 3, 2002 Exhibit 4.13 OFFICE AND INDUSTRIAL LEASE AGREEMENT between LIBERTY PROPERTY PHILADELPHIA LIMITED PARTNERSHIP V (“Landlord”) and APPTEC LABORATORY SERVICES, LLC (“Tenant”) Dated: December 3, 2002 TABLE OF CONTENTS (Single Tenant Office and Industrial) Page 1 Basic Lease Terms and Definitions 1 2. Premises 4 3. U |
|
| June 16, 2008 |
EX-4.15 4 dex415.htm LEASE AGREEMENT DATED AS OF AUGUST 31, 2007 Exhibit 4.15 LEASE AGREEMENT Basic Lease Information Lease Date: August 31, 2007. Landlord: 1201 Northland Drive LLC, a Minnesota limited liability company Landlord’s Address for Notices: 1201 Northland Drive LLC c/o Eagle Ridge Partners LLC 5753 Wayzata Boulevard St. Louis Park, MN 55416 with a required copy to: Fabyanske, Westra, H |
|
| June 16, 2008 |
GREATER ATLANTA COMMERCIAL BOARD OF REALTORS, INC. STANDARD COMMERCIAL LEASE AGREEMENT Exhibit 4.16 GREATER ATLANTA COMMERCIAL BOARD OF REALTORS, INC. STANDARD COMMERCIAL LEASE AGREEMENT THIS LEASE is made by and among Lonnie Pope (hereinafter called ?Landlord?), and ViroMed Laboratories, Inc. d/b/a Axios, Inc. (hereinafter called ?Tenant?), and Bryant & Associates hereinafter called ?Broker?) and Cushman & Wakefield of Georgia, Inc. (hereinafter called ?Co-Broker?). WITNESSETH: PRE |
|
| June 16, 2008 |
CFO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 EXHIBIT 12. |
|
| June 16, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2007 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| June 16, 2008 |
EXHIBIT 12.1 Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Ge Li, Chief Executive Officer of WuXi PharmaTech (Cayman) Inc. (the ?Company?), certify that: 1. I have reviewed this annual report on Form 20-F of the Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mater |
|
| June 16, 2008 |
EXHIBIT 13.1 Certification by the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. ? 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Ge Li, Chief Executive Officer of WuXi PharmaTech (Cayman) Inc. (the ?Company?), hereby certifies, to the best of his knowledge, that the Company?s annual report on Fo |
|
| June 16, 2008 |
EX-4.14 3 dex414.htm LEASE AGREEMENT DATED AS OF APRIL 30, 2008 Exhibit 4.14 COVER PAGE The capitalized terms in this Lease shall have the meanings ascribed to them below, and each reference to such term in the Lease shall incorporate such meaning therein as if fully set forth therein. Terms: Landlord: Highwoods Realty Limited Partnership, a North Carolina limited partnership d/b/a Highwoods Prope |
|
| June 16, 2008 |
CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13. |
|
| May 28, 2008 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| April 4, 2008 |
Agreement and Plan of Merger Exhibit 10.6 EXECUTION COPY AGREEMENT AND PLAN OF MERGER by and among AppTec Laboratory Services, Inc., Paul Acquisition Corporation, Paul (US) Holdco, Inc., and WuXi PharmaTech (Cayman) Inc. Dated as of January 3, 2008 TABLE OF CONTENTS Page ARTICLE 1 THE MERGER 2 1.1. The Merger 2 1.2. Effective Time; Closing 2 1.3. Effect of the Merger 2 1.4. Certificate of Incorpor |
|
| April 4, 2008 |
As filed with the Securities and Exchange Commission on April 4, 2008 Table of Contents As filed with the Securities and Exchange Commission on April 4, 2008 Registration No. |
|
| April 4, 2008 |
Exhibit 21.1 List of Subsidiaries ? WuXi AppTec (BVI) Inc., incorporated in the British Virgin Islands ? WuXi AppTec Holding Company Inc., incorporated in Delaware, United States ? WuXi AppTec, Inc., incorporated in Delaware, United States ? WuXi AppTec Co., Ltd., incorporated in the People?s Republic of China ? WuXi AppTec (Shanghai) Co., Ltd., incorporated in the People?s Republic of China ? Sha |
|
| April 4, 2008 |
CONSENT OF THE PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA Consent of The Pharmaceutical Research and Manufacturers of America Exhibit 23.9 April 1, 2008 Wuxi PharmaTech (Cayman) Inc 288 FuTe ZhongLu Waigaoqiao Free Trade Zone Shanghai 200131, PRC CONSENT OF THE PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA The Pharmaceutical Research and Manufacturers of America (“Company”) hereby consents to the references to the Company’s name in Wuxi PharmaTech |
|
| April 4, 2008 |
CONSENT OF KALORAMA INFORMATION Consent of Kalorama Information Exhibit 23.7 April 1, 2008 Wuxi PharmaTech (Cayman) Inc 288 FuTe ZhongLu Waigaoqiao Free Trade Zone Shanghai 200131, PRC CONSENT OF KALORAMA INFORMATION Kalorama Information (“Company”) hereby consents to the references to the Company’s name in Wuxi PharmaTech (Cayman) Inc.’s (the “Company”) Registration Statement on Form F-1 to be filed with the U.S. Securities and |
|
| April 4, 2008 |
FIRST AMENDMENT TO AGREEMENT AND PLAN OF MERGER Exhibit 10.7 FIRST AMENDMENT TO AGREEMENT AND PLAN OF MERGER THIS FIRST AMENDMENT TO AGREEMENT AND PLAN OF MERGER (this ?Amendment?) is executed as of January 31, 2008, by and among WuXi PharmaTech (Cayman) Inc., a Cayman corporation (?WuXi?), Paul (US) Holdco, Inc., a Delaware corporation and wholly owned subsidiary of WuXi (?Holdco?), Paul Acquisition Corporation, a Delaware corporation and whol |
|
| April 4, 2008 |
Consent of Frost & Sullivan Exhibit 23.8 April 3, 2008 Wuxi PharmaTech (Cayman) Inc 288 FuTe ZhongLu Waigaoqiao Free Trade Zone Shanghai 200131, PRC CONSENT OF FROST & SULLIVAN Frost & Sullivan (“Company”) hereby consents to the references to the Company’s name in Wuxi PharmaTech (Cayman) Inc.’s (the “Company”) Registration Statement on Form F-1 to be filed with the U.S. Securities and Exchange Co |
|
| March 17, 2008 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| February 12, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 WuXi PharmaTech (Cayman) Inc. (Name of Issuer) Ordinary Shares* American Depositary Shares (Title of Class of Securities) 929352102** (CUSIP Number) December 31, 2007 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 12, 2008 |
EX-99.(A) 2 dex99a.htm JOINT FILING AGREEMENT EXHIBIT A Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendme |
|
| January 29, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 WuXi PharmaTech (Cayman) Inc. (Name of Issuer) Ordinary Shares** American Depositary Shares (Title of Class of Securities) 929352102*** (CUSIP Number) December 31, 2007 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| January 24, 2008 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 WuXi PharmaTech (Cayman) Inc. (Name of Issuer) Ordinary Shares** American Depositary Shares (Title of Class of Securities) 929352102*** (CUSIP Number) December 31, 2007 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| January 4, 2008 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| November 13, 2007 |
6-K 1 d6k.htm FORM 6-K Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2007 Commission File Number: 001-33623 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of C |
|
| October 16, 2007 |
As filed with the Securities and Exchange Commission on October 16, 2007 As filed with the Securities and Exchange Commission on October 16, 2007 Registration No. |
|
| September 5, 2007 |
Table of Contents Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| August 9, 2007 |
424B4 1 d424b4.htm FORM 424(B)(4) Table of Contents Filed pursuant to rule 424(b)(4) Registration No. 333-144806 PROSPECTUS 13,188,979 American Depositary Shares WuXi PharmaTech (Cayman) Inc. (incorporated in the Cayman Islands) Representing 105,511,832 Ordinary Shares This is an initial public offering of American Depositary Shares, or ADSs, of WuXi PharmaTech (Cayman) Inc. Each ADS represents ei |
|
| August 8, 2007 |
CUSTOM SYNTHESIS AGREEMENT By and Between Merck & Co., Inc. WuXi PharmaTech Co., Ltd. Exhibit 10.7 CUSTOM SYNTHESIS AGREEMENT By and Between Merck & Co., Inc. and WuXi PharmaTech Co., Ltd. This Agreement (the ?Agreement?) confirms the mutual understanding by and between Merck & Co., Inc., a New Jersey corporation having a place of business at One Merck Drive, Whitehouse Station, NJ 08889 (?MERCK?), and WuXi PharmaTech Co., Ltd., a Chinese corporation having a place of business at B |
|
| August 8, 2007 |
Exhibit 10.6 PROCUREMENT AGREEMENT NO. EFFECTIVE DATE: FULLTIME EQUIVALENTS AGREEMENT FOR SERVICES Dated as of 1 October 2006 By and Between MERCK & CO., INC. And WUXI PHARMATECH CO., LTD. FTE Agreement NAME Last Revision Date NEW PROPRIETARY INFORMATION Not for use or disclosure outside Merck & Co., Inc., except under written agreement 1 PROCUREMENT AGREEMENT NO. 7458 EFFECTIVE DATE: 06-February- |
|
| August 8, 2007 |
As filed with the Securities and Exchange Commission on August 8, 2007 As filed with the Securities and Exchange Commission on August 8, 2007 Registration No. |
|
| August 7, 2007 |
As filed with the Securities and Exchange Commission on August 7, 2007 As filed with the Securities and Exchange Commission on August 7, 2007 Registration No. |
|
| August 7, 2007 |
Exhibit 1.1 WuXi PharmaTech (Cayman) Inc. 13,188,979 American Depositary Shares Each Representing Eight Ordinary Shares, Par Value US$0.02 Per Ordinary Share UNDERWRITING AGREEMENT [August 8], 2007 CREDIT SUISSE SECURITIES (USA) LLC Eleven Madison Avenue, New York, N.Y. 10010-3629 J.P. MORGAN SECURITIES INC. 270 Park Avenue, New York, N.Y. 10017 As Representatives of the Several Underwriters Dear |
|
| August 6, 2007 |
MASTER STARTING MATERIAL MANUFACTURING (CHINA) AGREEMENT EX-10.11 8 dex1011.htm MASTER STARTING MATERIAL MANUFACTURING (CHINA) AGREEMENT Exhibit 10.11 MASTER STARTING MATERIAL MANUFACTURING (CHINA) AGREEMENT This Master Manufacturing Agreement (“Agreement”) is made and entered into as of March 30, 2006 (“Effective Date”) by and between WuXi PharmaTech Co., LTD. (“Contractor”), having its principal place of business at NO. 1 Building, 288 FuTe ZhongLu, W |
|
| August 6, 2007 |
WuXi PharmaTech (Cayman) Inc. (incorporated in the Cayman Islands) FWP 1 dfwp.htm FREE WRITING PROSPECTUS Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration No. 333-144806 August 6, 2007 WuXi PharmaTech (Cayman) Inc. (incorporated in the Cayman Islands) WuXi PharmaTech (Cayman) Inc., or WuXi, has filed a registration statement on Form F-1 (including a prospectus) with the SEC for the offering to which this free writing prospectus relates. Befo |
|
| August 6, 2007 |
MASTER CHEMISTRY SERVICES AGREEMENT EX-10.9 6 dex109.htm MASTER CHEMISTRY SERVICE AGREEMENT Exhibit 10.9 MASTER CHEMISTRY SERVICES AGREEMENT This Master Chemistry Services Agreement (“Agreement”) is made and entered into as of December 1, 2005 (“Effective Date”) by and between WUXI PHARMATECH CO., LTD. (“Contractor”), having its principal place of business at Building 1, #288 Fu Te Zhong Lu, WaiGaoQiao Free Trade Zone, Shanghai, Chi |
